huaixu li

Mr. huaixu li

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in Science Progress
Verified
Journal Article
Open access
CFCheng Fang
Cheng Fang
GZGuangtao Zhang
Guangtao Zhang
SYShilu Ye
Shilu Ye
STShen Tian
Shen Tian
HLhuaixu li
huaixu li
CHCai Hong-qing
Cai Hong-qing
O6-methylguanine methyltransferase (MGMT), a pivotal DNA repair enzyme, has its dysregulation playing a substantial role in gliomagenesis, the development of therapeutic resistance, and patient prognosis. This narrative review is designed to offer an all-encompassing overview of the intricate regulatory mechanisms that govern MGMT expression in glioma cells. We systematically investigate the diverse levels of regulation that impact MGMT expression in glioma. These include epigenetic regulation, transcriptional control, post-translational modifications, and the influence exerted by the tumor microenvironment. Epigenetically, methylation of CpG islands within the MGMT promoter region represents a critical determinant for gene silencing. Conversely, histone modifications such as H3K4me3 augment MGMT expression. Transcriptionally, a complex network of transcription factors, which encompasses Sp1, p53, and NF-κB, along with signaling pathways like TGF-β, JAK/STAT, and PI3K/AKT, orchestrates MGMT expression in glioma cells. Furthermore, post-translational modifications of MGMT, such as phosphorylation and ubiquitination, are of pivotal importance in modulating its stability and enzymatic activity. The tumor microenvironment, with factors such as oxidative stress, hypoxia, and immune responses, also exerts a significant influence on MGMT expression. This narrative review delves deeper into the relationship between MGMT expression and drug resistance, especially resistance to alkylating chemotherapy agents, and accentuates the significance of evaluating MGMT expression for personalized glioma therapy. By elucidating these regulatory mechanisms, this review endeavors to enhance our understanding of MGMT's role in glioma biology and to provide insights for future therapeutic strategies aimed at surmounting current treatment challenges.

1 January 2022
Verified
Conference Paper
Open access
PDF file
XDXingliang Dai
Xingliang Dai
HLhuaixu li
huaixu li
Lei YeLei Ye
Lei Ye
HCHongwei Cheng
Hongwei Cheng
Dai X, et al. Brain Tumor Res Treat. 2022 Mar;10(Suppl):S265-1. https://doi.org/10.14791/btrt.2022.10.F-2554

10 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DZDeng Zekun
Deng Zekun
CHCai Hong-qing
Cai Hong-qing
YCYujia Chen
Yujia Chen
QLQi Liu
Qi Liu
HLhuaixu li
huaixu li
JWJing-Hai Wan
Jing-Hai Wan
Background: Salvage options for recurrent grade 4 glioma (GBM) remain limited and no single standard of care has been established after recurrence. Teniposide (VM-26) has been reintroduced into clinical practice, but its benefit when added to temozolomide (TMZ) plus bevacizumab (Bev) in recurrent grade 4 glioma remains unclear. Methods: This single-center, real-world exploratory study retrospectively enrolled 53 patients with recurrent grade 4 glioma who received either teniposide plus TMZ and Bev (VM26 + TMZ + Bev, n = 26) or TMZ plus Bev (TMZ + Bev, n = 27). The control group combined patients treated before teniposide became available again in China (2020–2022) with those treated concurrently with the triplet (2023–2026). Safety was assessed using the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0; tumor response was evaluated according to the Response Assessment in Neuro-Oncology (RANO) criteria on an intention-to-treat basis, and survival was estimated by the Kaplan–Meier method. Results: Median progression-free survival (PFS) was 7.8 months (95% confidence interval (CI), 4.9–10.9) in the VM26 + TMZ + Bev group versus 5.1 months (95% CI, 4.4–6.8) in the TMZ + Bev group (log-rank p = 0.037; unadjusted hazard ratio (HR) 0.50, 95% CI, 0.25–0.97), and median overall survival (OS) was 12.7 months (95% CI, 8.4–15.4) versus 8.5 months (95% CI, 7.3–9.7) (log-rank p = 0.042; unadjusted HR 0.47, 95% CI, 0.23–0.98). Multivariable adjustment strengthened these estimates, whereas propensity score weighting and matching gave estimates of the same direction that did not reach significance. The objective response rate (ORR) was 26.9% (7/26) versus 14.8% (4/27) (p = 0.327) and the disease control rate (DCR) was 80.8% versus 77.8% (p = 1.000). Grade ≥ 3 adverse events (AEs) occurred in 11.5% versus 7.4% of patients (p = 0.669); leukopenia and neutropenia were more frequent with teniposide (26.9% vs. 3.7%; p = 0.024) but lost significance after Benjamini–Hochberg correction (q = 0.122). No unexpected toxicity types were observed, although any-grade leukopenia and neutropenia were more frequent with teniposide and should be anticipated in clinical use. Conclusions: In this exploratory real-world cohort, adding teniposide to TMZ plus Bev was associated with longer PFS and OS and a numerically higher ORR, without a significant increase in grade ≥ 3 toxicity, although any-grade leukopenia and neutropenia were more frequent and should be anticipated; however, treatment era could not be fully separated from treatment effect: in an era-matched analysis restricted to the concurrently treated cohorts, the direction of the effect was preserved but did not reach significance. The survival differences rested on a small number of events and were not robust to reclassification of individual patient outcomes. These findings warrant confirmation in prospective randomized studies.

1 April 2026 in Genes & Diseases
Verified
Journal Article
Open access
HCHongqing Cai
Hongqing Cai
XLXiaohong Lu
Xiaohong Lu
WFWenwen Fan
Wenwen Fan
CFCheng Fang
Cheng Fang
FMFengchun Mu
Fengchun Mu
HLhuaixu li
huaixu li

12 October 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
HLhuaixu li
huaixu li
CHCai Hong-qing
Cai Hong-qing
STShen Tian
Shen Tian
YCYujia Chen
Yujia Chen
QLQi Liu
Qi Liu
JWJing-Hai Wan
Jing-Hai Wan
Background/Objectives: Leptomeningeal metastasis (LM) is a severe complication of solid tumors. Cerebrospinal fluid (CSF) cytology is only about 70% sensitive on a single examination, and objective markers are needed. Methods: CSF from 49 patients with LM and 16 with intracranial disease without LM was analyzed by targeted LC–MS in a training batch (n = 30) and a temporally independent validation batch (n = 35). Metabolites selected by both LASSO and random forest entered a logistic regression model, which was applied unchanged to the validation batch and evaluated by repeated and nested cross-validation on all 65 samples. Results: Hydroxyphenyllactic acid, argininosuccinic acid and norepinephrine were selected by both algorithms. The model reached an AUC of 0.954 in the training batch and 0.839 (95% CI 0.687–0.991) in the validation batch. In repeated cross-validation on all 65 samples, the AUC was 0.790 (95% CI 0.655–0.924), with sensitivity 0.714 and specificity 0.938; nested cross-validation gave 0.747. Conclusions: A three-metabolite CSF panel discriminates LM from non-LM and retains discrimination under cross-validation and in a temporally independent batch. It is a candidate adjunct to cytology and imaging whose specificity, based on 16 controls, requires confirmation in larger cohorts.

10 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HLhuaixu li
huaixu li
CHCai Hong-qing
Cai Hong-qing
XLXiaohong Lu
Xiaohong Lu
QLQi Liu
Qi Liu
YCYujia Chen
Yujia Chen
JWJing-Hai Wan
Jing-Hai Wan
Objective: Real-world data on Ommaya reservoir-based cerebrospinal fluid (CSF) chemotherapy for leptomeningeal metastasis (LM) in the targeted-therapy era are limited. We describe its safety and survival and explore prognostic factors in lung adenocarcinoma-associated LM. Methods: We retrospectively reviewed 68 patients with LM treated with Ommaya reservoir implantation and CSF chemotherapy. Overall survival (OS) was estimated from LM diagnosis and from implantation, and an exploratory multivariable Cox regression was performed in patients with actionable driver mutations receiving targeted therapy. Results: Device-related complications occurred in six patients (8.8%), including three catheter malpositions after freehand placement; chemotherapy-related adverse effects occurred in four (5.9%). After a median follow-up of 12.8 months, 14 patients (20.6%) had died, 10 of CNS progression. Median OS was not reached from diagnosis (24-month OS 67.8%) and 18.7 months from implantation (24-month OS 48.3%). In the exploratory analysis (n = 46), KPS, age, and EGFR mutation subtype were associated with OS from both time origins. Conclusions: Ommaya reservoir-based CSF chemotherapy was feasible with few device-related complications. Because all patients were treated and most had lung adenocarcinoma receiving targeted therapy, the favorable survival cannot be attributed to the reservoir or generalized to other primary tumors; prognostic factors require prospective validation.